Engineered immune cells show promise against stubborn lymphoma

NCT ID NCT03105336

Completed Disease control Sponsor: Kite, A Gilead Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a one-time treatment using a person's own immune cells, modified to attack cancer, in 159 adults with follicular or marginal zone lymphoma that had returned after at least two prior therapies. The main goal was to see how many patients had their tumors shrink or disappear. While the therapy can lead to remission, ongoing monitoring and potential follow-up treatments mean it is considered disease control rather than a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma indolent B-cell non-Hodgkin lymphoma Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOLLICULAR LYMPHOMA INDOLENT NON-HODGKIN LYMPHOMA MARGINAL ZONE LYMPHOMA

Contacts and locations

Locations

Banner MD Anderson Cancer Center

Gilbert, Arizona, 85234, United States
Centre Hospitalier Lyon Sud

Pierre-Bénite, 69495, France
Centre Hospitalier Régional Universitaire de Lille

Lille, 59037, France
Columbia University Medical Center

New York, New York, 10032, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Fred Hutchinson Cancer Research Center

Seattle, Washington, 98109, United States
Georgetown Lombardi Comprehensive Cancer Center

Washington D.C., District of Columbia, 20007, United States
H Lee Moffitt Cancer Center

Tampa, Florida, 33612, United States
Hackensack University Medical Center - John Theurer Cancer Center

Hackensack, New Jersey, 07601, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Ohio State University Medical Center

Cleveland, Ohio, 44106, United States
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
USC Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
University of California Los Angeles

Los Angeles, California, 90095, United States
University of Miami Hospital and Clinics

Miami, Florida, 33136, United States
University of Rochester Medical Center (URMC)

Rochester, New York, 14642, United States
Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.